Wegovy Review: What the Clinical Evidence and Real-World Experience Show

The biggest misconception about Wegovy: it works the same for everyone

Search for a Wegovy review and you will find accounts at both ends, people who lost 20% of their body weight and people who stopped after two months because nausea made it unworkable. A common take-away is that the medicine is either transformative or ineffective, depending on who's speaking. That framing misses something important: the clinical evidence shows a consistent average, not a uniform outcome. Individual results sit across a range, and where you land depends on your starting biology, your dose, how long you stay on treatment, and whether behavioural support is part of the picture.

The STEP 1 trial, published in the New England Journal of Medicine, randomised 1,961 adults with a BMI of 30 or more (or 27 with a weight-related condition) to semaglutide 2.4mg or placebo over 68 weeks. Average weight reduction on semaglutide was roughly 15%, compared with about 2.4% on placebo. Around one in three participants lost more than 20%. Those are population-level statistics, not a personal forecast, but they tell you the medicine has a meaningful biological effect, not because people suddenly found willpower they didn't have before, but because appetite suppression and slower gastric emptying genuinely change hunger signals. That distinction matters, and it is worth sitting with for a moment before reading the rest.

The UK semaglutide reviews that read as disappointments often share a pattern: expectations were set by the headline figure without accounting for dose titration time, GI side effects in the early weeks, or the role of diet and activity alongside the injection. Understanding the mechanism makes the reviews easier to read critically, and reading a wider range of reviews about Wegovy can help you build a more balanced picture before starting treatment.

What the side-effect picture actually looks like across the dose schedule

Wegovy is titrated gradually: the maintenance pathway runs from 0.25mg up through 0.5mg, 1.0mg and 1.7mg before reaching the 2.4mg maintenance dose, with roughly four weeks at each level. The MHRA also approved a higher 7.2mg dose in early 2026, with a dedicated single-dose pen confirmed in April 2026 for adults with a BMI of 30 or above. Most people start at 0.25mg (a tolerability step, not a therapeutic one) and the side effects that draw the most online comment are heaviest during dose increases.

Nausea is the most frequently reported; it typically eases within one to two weeks of each new dose. Constipation, loose stools, reflux and burping are also common in the first few weeks. Fatigue and mild headaches appear in some people, usually early on. These effects are real, and it is worth going in with eyes open. They are also the reason the schedule exists: a gradual increase gives the body time to adjust. Because so much of the early experience happens at the starting level, accounts from people sharing their Wegovy 0.5mg experience are particularly useful for understanding what the first weeks on the dose schedule can feel like. The NHS semaglutide page sets out which side effects to manage at home and which warrant medical attention, pancreatitis (severe stomach pain that radiates to the back) and signs of a serious allergic reaction being the situations that need same-day medical contact rather than a wait-and-see approach.

A smaller subset of people on semaglutide report changes in mood. If that is a concern, our page on Wegovy and emotional side effects covers what is currently known and what to flag with your prescriber.

Who Wegovy is licensed for in the UK, and how that compares to NHS eligibility

The licensed criteria per the UK summary of product characteristics are: adults with a BMI of 30 or above, or a BMI of 27 to 29.9 with at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. The licence does not differentiate between NHS and private routes, that is decided by commissioning, not the medicine itself.

NICE's appraisal of semaglutide for weight management, TA875, recommends it within specialist weight management services, for a maximum of two years, for adults with a BMI of 35 or above and at least one weight-related comorbidity. The NHS criteria are therefore considerably stricter than the licensed population, and most NHS services carry significant waiting times. Private prescription via a regulated online pharmacy is the route for people who meet the licensed criteria but fall outside the NICE thresholds, or who prefer not to wait. For context on what private treatment costs and what an all-in price should cover, our treatment overview explains what to look for.

BMI is a starting point for a conversation, not a final decision. A prescriber will look at your full medical history, current medicines and any contraindications before approving treatment. People who are pregnant, breastfeeding or trying to conceive are advised not to use Wegovy, and the medicine is not licensed for anyone under 18.

Reading Wegovy reviews online: what the pattern tells you

Community reviews of semaglutide tend to cluster around a few recurring themes. Positive accounts most often cite reduced appetite as the mechanism that made the difference, not dramatic willpower, but the experience of simply feeling full sooner and thinking about food less. Critical reviews more often describe stopping early due to persistent nausea, or plateau frustration when weight loss slowed before reaching the maintenance dose. Both experiences are real and reflect the clinical data: the trial figures are averages drawn from a population with genuine variation underneath them.

A practical note our prescribers hear fairly often: people who started on a full-strength dose elsewhere, experienced significant side effects, and concluded the medicine did not suit them, sometimes find the titration schedule changes things. That is a clinical conversation, not a general recommendation. If you are exploring whether semaglutide is the right fit, our semaglutide overview covers the mechanism and evidence in more depth, and weight-loss-specific Wegovy experiences give a more structured look at the evidence behind the headline figures. For a broader view of how this medicine compares in practice, our curated Wegovy reviews resource is a useful next step alongside reading the clinical data.

If you would like a clinician to assess whether Wegovy is suitable for you, check your eligibility with our prescribing team, the consultation is free, and a GPhC-registered prescriber reads every submission.